newsmetry
rusign inget started
macro

Zai Lab Q3 revenue falls 7% as net loss widens to $46.14M

Zai Lab's Q3 2026 revenue was $108.21M, down about 7% year on year, and its net loss widened to $46.14M, per a TradingView summary of the 10-Q.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Zai Lab reported third-quarter revenue of $108.21 million, about 7% below the year-earlier level, according to a TradingView summary of its 10-Q filing with the SEC. Sales of ZEJULA, OPTUNE and VYVGART declined, and that drop was only partly offset by growth in NUZYRA, up 37%, and XACDURO, up 31%.

The net loss widened to $46.14 million from $35.96 million a year earlier, and the loss per diluted share came in at $0.04 versus $0.03. Operating results were also squeezed by costs for products and research spending. KarXT, launched in June 2026, contributed $2.0 million of revenue in the quarter.

The company also plans a global Phase 3 trial of zoci combined with atezolizumab in first-line extensive-stage small cell lung cancer, citing encouraging early-stage data.

why it matters

For investors, the quarter suggests that growth in newer antibiotics and the KarXT launch is not yet covering the decline in older products, while losses keep growing. The key question for upcoming reports is when revenue will start to outpace expenses.

market impact

Zai Lab shares: weaker revenue and a bigger loss put pressure on the stock

  • Zai Lab shares pressure down — revenue fell while the net loss widened on higher operating costs

tags

EarningsStockUnited States

instruments

Zai Lab sharesZLAB

sources

  1. Zai Lab 3Q 2026: Revenue $108.21M, EPS ($0.04) — 10-Q Summary — TradingView, 5 November 2026 at 11:51 UTC
  2. ARKO 3Q 2026: Revenue $2.39B, EPS $0.08 — 10-Q Summary — TradingView, 5 November 2026 at 12:11 UTC
  3. Commerce 3Q 2026: Revenue $84.25M, EPS ($0.04) — 10-Q Summary — TradingView, 5 November 2026 at 12:11 UTC
  4. Certara 3Q 2026: Revenue $94.9M, EPS $0.04 — 10-Q Summary — TradingView, 5 November 2026 at 12:21 UTC
  5. Apyx Medical 3Q 2026: Revenue $14.03M, EPS ($0.04) — 10-Q Summary — TradingView, 5 November 2026 at 16:01 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories